[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult-t-cell-leukemialymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult-t-cell-leukemialymphoma":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,73,108,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":55,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100514411","a-registry-for-people-with-t-cell-lymphoma-100514411",false,"NCT05978141","A Registry for People With T-cell Lymphoma","The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens","Inclusion Criteria:\n\n* Written informed consent\n* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.\n* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):\n\n  * T-cell prolymphocytic leukemia\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Aggressive NK-cell leukemia\n  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood\n  * Chronic active EBV infection of T- and NK-cell type, systemic form\n  * Hydroa vacciniforme-like lymphoproliferative disorder\n  * Adult T-cell leukemia\u002Flymphoma\n  * Extranodal NK\u002FT-cell lymphoma, nasal type\n  * Enteropathy-associated T-cell lymphoma\n  * Monomorphic epitheliotropic intestinal T-cell lymphoma\n  * Intestinal T-cell lymphoma, not otherwise specified (NOS)\n  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract\n  * Hepatosplenic T-cell lymphoma\n  * Subcutaneous panniculitis-like T-cell lymphoma\n  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)\n  * Sézary syndrome\n  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)\n  * Primary cutaneous Gamma-Delta T-cell lymphoma\n  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma\n  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)\n  * Peripheral T-cell lymphoma, not otherwise specified\n  * Angioimmunoblastic T-cell lymphoma\n  * Follicular T-cell lymphoma\n  * Nodal peripheral T-cell lymphoma with TFH phenotype\n  * Anaplastic large cell lymphoma, ALK-positive\n  * Anaplastic large cell lymphoma, ALK-negative\n  * Breast-implant associated anaplastic large cell lymphoma.\n* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.\n\nExclusion Criteria:\n\n* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.\n* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.","ALL",{"count":18,"type":19},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"T-cell Lymphoma","NK-Cell Lymphoma","T-cell Prolymphocytic Leukemia","T-cell Large Granular Lymphocytic Leukemia","Chronic Lymphoproliferative Disorder of NK Cells","Aggressive NK-cell Leukemia","Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)","Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood","Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form","Hydroa Vacciniforme-Like Lymphoproliferative Disorder","Adult T-cell Leukemia\u002FLymphoma","Extranodal NK\u002FT-cell Lymphoma, Nasal Type","Enteropathy-associated T-cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Intestinal T-Cell Lymphoma, Not Otherwise Specified","Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","Hepatosplenic T-cell Lymphoma","Subcutaneous Panniculitis-Like T-Cell Lymphoma","Mycosis Fungoides","Sezary Syndrome","Primary Cutaneous Anaplastic Large Cell Lymphoma","Primary Cutaneous T-cell Lymphoma","Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Anaplastic Large Cell Lymphoma, ALK-Positive","Anaplastic Large Cell Lymphoma, ALK-negative","Breast Implant-Associated Anaplastic Large Cell Lymphoma",[56,57,58,59,60],"23-190","T-cell lymphoma","Memorial Sloan Kettering Cancer Center","T-cell Lymphoma Master Repository","TCLMR","RECRUITING","2026-05-18",{"date":64,"type":65},"2026-05-20","ACTUAL",{"date":67,"type":65},"2023-07-27",{"date":69,"type":19},"2030-07-27",{"name":58,"class":71},"OTHER",26,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":93,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100620332","phase-2-ruxolitinib-maintenance-post-hematopoietic-stem-cell-transplant-t-cell-lymphoma-100620332","NCT07356245","Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma","Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma","Inclusion Criteria:\n\n1. Adult patients with T-cell lymphoma \\[PTCL (all subtypes), T-PLL, ATLL, and CTCL (all subtypes)\\] in partial or complete remission between day +35 and +120 from auto-SCT or allo-SCT\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less\n3. Adequate hematologic function defined by absolute neutrophil count (ANC) \\> 1000\u002Fmm3 without granulocyte colony-stimulating factor (G-CSF) for at least 3 days, platelets \\> 50K\u002Fmm3 without transfusion for at least 3 days and hemoglobin (Hb) \\> 8.0 g\u002FdL without transfusion for at least 3 days.\n4. Adequate organ function defined by total Bilirubin \\\u003C 1.5 x ULN, alanine aminotransferase (ALT) \\\u003C\u002F= 3 x ULN, CKD-EPI eGFR ≥ 30 ml\u002Fmin, SpO2 \\> 92% without supplemental oxygen.\n5. Able to tolerate oral or enteral medications.\n6. Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.\n7. Able to read and sign informed consent.\n\nExclusion Criteria:\n\n1. Anaplastic lymphoma kinase (ALK)+ or Dual specificity 22 (DUSP22)+ ALCL with low international prognostic index (IPI) score (\\\u003C2) in first complete remission.\n2. Progressive disease or any other systemic therapy post-SCT (radiation allowed)\n3. Disease progression to Ruxolitinib previously\n4. GvHD requiring systemic therapy.\n5. Active uncontrolled infections.\n6. Active thrombotic active microangiopathy requiring therapy.\n7. History of veno-occlusive disorder post-transplant\n8. Use of platelets antiaggregant or anticoagulants deemed to be unsafe to be held in case of thrombocytopenia.\n9. History of life-threatening bleeding defined as any bleeding that required invasive procedures or involving central nervous system.\n10. Pregnancy (positive Beta HCG test in a woman with childbearing potential defined as not postmenopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\n11. Uncontrolled Hepatitis B\u002FC, HIV, tuberculosis, mycobacterium, or fungal infection.\n12. Exposure to other investigational drugs within 4 weeks before enrollment.\n13. Grade ≥ 3 non-hematologic toxicity from SCT that has not resolved to grade ≤ 2.\n14. Myocardial infarction or stroke within 1 year of study entry.\n15. Any uncontrolled medical problem at the discretion of the investigator that would pose a risk to the patient.","18 Years",{"count":82,"type":19},44,"INTERVENTIONAL",[85],"PHASE2","This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The \"graft\" is the donor blood cells that patients get during the transplant. The \"host\" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.",[24,88,89,90,26,91,34,92],"Graft Versus Host Disease","Lymphoma, T-Cell","Peripheral T Cell Lymphoma","Cutaneous T Cell Lymphoma","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",[94,95,96,97],"stem cell transplant","graft versus host disease","lymphoma","leukemia","2026-04-10",{"date":100,"type":65},"2026-04-15",{"date":102,"type":65},"2026-02-12",{"date":104,"type":19},"2027-01-31",{"name":106,"class":71},"Jonathan Brammer",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":83,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":107},"100441709","phase-2-two-step-haplo-with-radiation-conditioning-100441709","NCT05031897","Two Step Haplo With Radiation Conditioning","A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning","Inclusion Criteria:\n\n* Radiation-based cohort diagnoses:\n\n  * Acute myeloid leukemia\n  * Acute lymphoid leukemia in remission\n  * Myelodysplasia (MDS)\n  * Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement\n  * Multiple myeloma\n  * Chronic myeloid leukemia\n  * Myelofibrosis\n  * Myeloid malignancy not otherwise specified\n  * Chronic myelomonocytic leukemia\n  * Essential thrombocytopenia or polycythemia vera\n  * T cell leukemia\n  * T cell lymphoma without significant lymph node disease burden\n  * Any hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable\n  * Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.\n  * Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n* Chemotherapy-based cohort diagnoses:\n\n  * Hodgkin or non-Hodgkin lymphoma\n  * Small lymphocytic lymphoma\u002FCLL\n  * Any other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease\n  * Hematological malignancy in patients who cannot receive \\> 2 Gy radiation\n  * Aplastic anemia and other non-malignant hematologic dyscrasias\n  * Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n* Human leukocyte antigen (HLA) identical cohort diagnoses:\n\n  \\* Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included).\n* Left ventricular ejection fraction of \\>= 50%\n* Diffusion lung capacity of oxygen \\>= 50% and forced expiratory volume at 1 second \\>= 50% of predicted corrected for hemoglobin\n* Serum bilirubin =\\\u003C 1.8\n* Aspartate aminotransferase or alanine aminotransferase =\\\u003C 2.5 x upper limit of normal\n* Creatinine clearance of \\>= 60 mL\u002Fmin\n* Patients must have adequate Karnofsky performance status (KPS) and Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) scores:\n\n  * Patients \\\u003C age 60 years must have a KPS of \\>= 60% and an HCT-CI score of 5 or less\n  * Patients aged 60 to 65 years must have a KPS of \\>= 60% and an HCT-CI score of 4 or less\n  * Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less\n  * Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less\n  * (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator (PI) and at least 1 co-investigator (CI) not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities\n* Patients must be willing to use contraception if they have childbearing potential\n* Patient or patient's guardian is able to give informed consent\n* Patients should have a life expectancy of \\>= 6 months for reasons other than their underlying hematologic\u002Foncologic disorder\n* Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol\n* Patients should not be:\n\n  * Human immunodeficiency virus positive\n  * Have active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and\u002For a negative cerebral spinal fluid analysis\n* Pregnant or breastfeeding",{"count":116,"type":19},63,[85],"This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.",[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adult T-Cell Leukemia\u002FLymphoma","Aplastic Anemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Essential Thrombocythemia","Hematopoietic and Lymphatic System Neoplasm","Hodgkin Lymphoma","Multiple Myeloma","Myelodysplastic Syndrome","Myelofibrosis","Myeloid Neoplasm","Non-Hodgkin Lymphoma","Polycythemia Vera","Small Lymphocytic Lymphoma","2025-10-28",{"date":139,"type":65},"2025-10-30",{"date":141,"type":65},"2021-10-25",{"date":143,"type":19},"2032-04",{"name":145,"class":71},"Thomas Jefferson University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":83,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":107},"100605215","phase-2-venetoclax-combined-with-azacitidine-chidamide-vindesine-and-dexamethasone-in-newly-diagnosed-etp-all-like-patients-100605215","NCT07159620","Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","A Prospective Single-Arm Clinical Study of Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","Inclusion Criteria:\n\n1. Age: \\>14 to 65 years (inclusive).\n2. Diagnosis: Patients diagnosed with ETP-ALL like disease meeting the following flow cytometry immunophenotypic criteria:\n\n   ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate ≤75%, and positive for at least one myeloid\u002Fstem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.\n\n   Near-ETP-ALL: CD7+, CD1a-, CD8-, CD5 positivity rate \\>75%, AND positive for at least one myeloid\u002Fstem cell antigen marker (including but not limited to CD34, CD117, HLA-DR, CD13, CD33, CD11b, or CD65); MPO negative.\n\n   T-ALL with myeloid mutations: FLT3, DNMT3A, STAG2, IDH1\u002FIDH2, RUNX1, EZH2, WT1, ASXL1\u002FASXL2, SF3B1, TET2, BCOR, BCORL1.\n3. Newly diagnosed patients who have not received any prior induction therapy before enrollment (excluding hydroxyurea, dexamethasone, low-dose cytarabine, venetoclax with a cumulative dose \\\u003C0.5g, and leukapheresis).\n4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n5. Expected survival \\>6 months.\n6. Demonstrated capacity to understand the study and willingness to provide informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential\n2. Presence of uncontrolled active infection (including bacterial, fungal, or viral infections); concurrent active HBV, HCV, or HIV infection.\n3. Severe Organ Dysfunction:\n\n   Cardiac Insufficiency: Left ventricular ejection fraction (LVEF) ≤40%, OR history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia.\n\n   Respiratory Failure: Partial pressure of arterial oxygen (PaO₂) ≤60 mmHg. Hepatic Impairment: Total bilirubin ≥2 times the upper limit of normal (ULN), OR alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times ULN.\n\n   Renal Impairment: Serum creatinine ≥2 mg\u002FdL, OR creatinine clearance ≤30 mL\u002Fmin\u002F1.73m².\n\n   Hypersensitivity: History of hypersensitivity to any of the study drugs or compounds of similar chemical structure.\n4. Presence of central nervous system (CNS) leukemia.\n5. Any other condition deemed by the investigator to make the subject unsuitable for participation in this trial.","14 Years","65 Years",{"count":156,"type":19},27,[85],"ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .",[34],"2025-09-05",{"date":162,"type":65},"2025-09-08",{"date":164,"type":19},"2025-09-01",{"date":166,"type":19},"2030-09-01",{"name":168,"class":71},"The First Affiliated Hospital of Soochow University"]